Gilead’s CFO and Executive Vice President to depart in 2020
pharmafile | May 1, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Gilead, appointment, pharma
Gilead has announced that Robin Washington, the company’s Senior Vice President and Chief Financial Officer of more than a decade, is set to step down from her role effective 1 March 2020.
Washington joined the company in 2008 as CFO, and was promoted to Executive Vice President in 2014. In her role, she oversees Gilead’s Global Finance and Information Technology organisations.
Prior to the move to Gilead, Washington served as CFO at software firm Hyperion Solutions, which was acquired by Oracle Corporation in 2007 to become Oracle Hyperion, and she held a number of executive roles at PeopleSoft before that, most recently as Senior Vice President and Corporate Controller. In the past, she has also held positions on the boards of Tektronix, MIPS Technologies, and she currently resides on the Board of Directors for Honeywell International and Salesforce.com, and on the Board of Visitors for Graziadio School of Business and Management, Pepperdine University. The same day of the announcement of her departure from Gilead, she was elected to Alphabet’s board.
Washington has agreed to continue in her role while Gilead searches for her replacement. If a replacement is found before her departure date of 1 March next year, she will remain at the company in an advisory capacity through the completion of the company’s reporting of its 2019 financial results.
“During my short time here, I have been impressed with the strategic expertise that Robin brings to her role and the dedication she has for our mission and the patients we serve. It is equally clear that she has built a strong team across the organisations she leads,” commented Daniel O’Day, Chairman and Chief Executive Officer at Gilead. “Robin is an outstanding leader and it comes as no surprise that she has agreed to remain with Gilead through the completion of the company’s reporting of 2019 financial results.”
Washington commented on the announcement: “It has been my great honour to serve as Gilead’s CFO for more than 10 years, and to work alongside the talented team we have in place across our CFO organisation and Gilead at large. Together, we’ve played a role in the important work this company does to deliver ground-breaking treatment advances to people all over the world. I am committed to working with Dan, the rest of the leadership team and my colleagues over the coming months to ensure that this transition process is a seamless one.”
Matt Fellows
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …
